Who is sponsoring NCT07441980?

NCT07441980 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT07441980?

Interventions in NCT07441980: CAR-T cells chimeric antigen receptor T cells.

What condition does NCT07441980 study?

NCT07441980 studies Relapsed/Refractory Acute Myeloid Leukemia(AML).

Is NCT07441980 still recruiting?

NCT07441980 is currently not yet recruiting. Last updated 2 March 2026.

Last reviewed 2026-03-02 · How we verify

NCT07441980

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia

Not yet recruiting Phase 1 Last updated 2 March 2026

What this trial tests

Phase 1 trial testing CAR-T cells chimeric antigen receptor T cells in Relapsed/Refractory Acute Myeloid Leukemia(AML) in 18 participants. Not yet recruiting.

Timeline

2 March 2026

Primary endpoint
31 December 2026

30 June 2028

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	2 March 2026
Primary completion	31 December 2026
Estimated completion	30 June 2028
Sites	1 location across China

Drugs / interventions tested

CAR-T cells chimeric antigen receptor T cells — full drug profile →

Conditions studied

Relapsed/Refractory Acute Myeloid Leukemia(AML) — all drugs for Relapsed/Refractory Acute Myeloid Leukemia(AML) →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

Adults 18 to 70, any sex, with Relapsed/Refractory Acute Myeloid Leukemia(AML). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Clinical Study to Investigate the Safety and Efficacy of CT1390B in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07441980 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 2 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07441980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing